



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-------------------------|------------------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------------|------------------------|----------------------|--|--|
| A01 | 3,116,282 | 12/31/63 | Hunter | |
| A02 | 3,891,623 | 6/24/75 | Vorbruggen <i>et al.</i> | |
| A03 | 3,480,613 | 11/25/69 | Walton | |
| A04 | 4,209,613 | 6/24/80 | Vorbruggen | |
| A05 | 4,294,766 | 10/13/81 | Schmidt <i>et al.</i> | |
| A06 | 4,605,659 | 8/12/86 | Verheyden <i>et al.</i> | |
| A07 | 4,689,404 | 8/25/87 | Kawada <i>et al.</i> | |
| A08 | 4,754,026 | 6/28/88 | Kawada <i>et al.</i> | |
| A09 | 5,034,394 | 7/23/91 | Daluge | |
| A10 | 5,122,517 | 6/16/92 | Vince <i>et al.</i> | |
| A11 | 5,200,514 | 4/06/93 | Chu | |
| A12 | 5,322,955 | 6/21/94 | Matsumoto <i>et al.</i> | |
| A13 | 5,372,808 | 12/13/94 | Blatt <i>et al.</i> | |
| A14 | 5,391,769 | 2/21/95 | Matsumoto <i>et al.</i> | |
| A15 | 5,676,942 | 10/14/97 | Testa <i>et al.</i> | |
| A16 | 5,738,845 | 4/14/98 | Imakawa | |
| A17 | 5,744,600 | 4/28/98 | Mansuri <i>et al.</i> | |
| A18 | 5,750,676 | 5/12/98 | Vorbruggen <i>et al.</i> | |
| A19 | 5,830,455 | 11/3/98 | Valtuena <i>et al.</i> | |
| A20 | 5,849,696 | 12/15/98 | Chretien <i>et al.</i> | |
| A21 | 5,908,621 | 6/1/99 | Glue <i>et al.</i> | |
| A22 | 5,928,636 | 7/27/99 | Alber <i>et al.</i> | |
| A23 | 5,942,223 | 8/24/99 | Bazer <i>et al.</i> | |
| A24 | 5,977,061 | 11/2/99 | Holy and De Clerq | |
| A25 | 5,977,325 | 11/2/99 | McCarthy <i>et al.</i> | |
| A26 | 5,980,884 | 11/9/99 | Blatt <i>et al.</i> | |
| A27 | 6,002,029 | 12/14/99 | Hostetler <i>et al.</i> | |
| A28 | 6,063,628 | 5/16/00 | Loeb <i>et al.</i> | |
| A29 | 6,140,310 | 10/31/00 | Glazier | |
| A30 | 6,153,594 | 11/28/00 | Børretzen <i>et al.</i> | |

LAI-2881671v1

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| | FILING DATE | ART UNIT |
| | June 27, 2003 | 1623 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------------|------------------------|----------------------|--|--|
| A31 | 6,156,501 | 12/05/00 | McGall et al. | |
| A32 | 6,248,878 | 6/19/01 | Matulic-Adamic et al. | |
| A33 | 6,271,212 | 8/07/01 | Chu et al. | |
| A34 | 6,340,690 | 1/22/02 | Bachand et al. | |
| A35 | 6,369,040 | 4/09/02 | Acevedo et al. | |
| A36 | 6,395,716 | 5/28/02 | Gosselin et al. | |
| A37 | 6,444,652 | 9/3/02 | Gosselin et al. | |
| A38 | 6,455,508 | 9/24/02 | Ramasamy et al. | |
| A39 | 6,566,344 | 5/20/03 | Gosselin et al. | |
| A40 | 6,569,837 | 5/27/03 | Gosselin et al | |
| A41 | 6,596,700 | 7/22/03 | Sommadossi et al. | |
| A42 | 6,605,614 | 8/12/03 | Bachand et al. | |
| A43 | 6,660,721 | 12/9/03 | Devos et al. | |
| A44 | 6,748,161 | 6/8/04 | Ko et al. | |
| A45 | 6,777,395 | 8/17/04 | Bhat et al. | |
| A46 | 6,784,161 | 8/31/04 | Ismaili et al. | |
| A47 | 6,784,166 | 8/31/04 | Devos et al. | |
| A48 | 6,787,526 | 9/7/04 | Bryant et al. | |
| A49 | 6,812,219 | 11/2/04 | LaColla et al. | |
| A50 | 6,815,542 | 11/9/04 | Hong et al. | |
| A51 | 6,831,069 | 12/14/04 | Tam et al. | |
| A52 | 6,833,361 | 12/21/04 | Hong et al. | |
| A53 | 6,846,810 | 1/25/05 | Martin et al. | |
| A54 | 6,875,751 | 4/5/05 | Imbach et al. | |
| A55 | 6,908,924 | 6/21/05 | Watanabe et al. | |
| A56 | 6,914,054 | 7/5/05 | Sommadossi et al. | |
| A57 | 6,927,291 | 8/9/05 | Jin et al. | |
| A58 | 6,946,115 | 9/20/05 | Erion et al. | |
| A59 | 6,946,450 | 9/20/05 | Gosselin et al. | |
| A60 | 6,949,522 | 9/27/05 | Otto et al. | |

LAI-2881671v1

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| | FILING DATE | ART UNIT |
| | June 27, 2003 | 1623 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------------|------------------------|----------------------|--|--|
| A61 | 7,056,895 | 6/6/06 | Ramasamy et al. | |
| A62 | 7,094,770 | 8/22/06 | Wantanabe et al. | |
| A63 | 7,101,861 | 9/5/06 | Sommadossi et al. | |
| A64 | 7,105,493 | 9/12/06 | Sommadossi et al. | |
| A65 | 7,144,868 | 12/5/06 | Roberts et al. | |
| A66 | 7,148,206 | 12/12/06 | Sommadossi et al. | |
| A67 | 7,151,089 | 12/19/06 | Roberts et al. | |
| A68 | 7,157,434 | 1/2/07 | Keicher et al. | |
| A69 | 7,169,766 | 1/30/07 | Sommadossi et al. | |
| A70 | 7,202,224 | 4/10/07 | Eldrup et al. | |
| A71 | 2003/0039630 | 2/27/03 | Albrecht | |
| A72 | 2003/0124512 | 7/03/03 | Styuver | |
| A73 | 2003/0225028 | 12/4/03 | Gosselin et al. | |
| A74 | 2003/0225037 | 12/4/03 | Storer et al. | |
| A75 | 2004/0229839 | 11/18/04 | Babu et al. | |
| A76 | 2004/0248844 | 12/9/04 | Ismaili et al. | |
| A77 | 2004/0259934 | 12/23/04 | Olsen et al. | |
| A78 | 2004/0266996 | 12/30/04 | Rabi et al. | |
| A79 | 2005/0020825 | 1/27/05 | Storer et al. | |
| A80 | 2005/0031588 | 2/10/05 | Sommadossi et al. | |
| A81 | 2005/0038240 | 02/17/05 | Connolly et al. | |
| A82 | 2005/0113330 | 5/26/05 | Bryant et al. | |
| A83 | 2005/0137141 | 06/23/05 | Hilfinger et al. | |
| A84 | 2005/0215511 | 09/29/05 | Roberts et al. | |
| A85 | 2006/0040890 | 02/23/06 | Martin et al. | |
| A86 | 2006/0111311 | 05/25/06 | Keicher et al. | |
| A87 | 2006/0194835 | 08/31/06 | Dugourd et al. | |
| A88 | 2006/0241064 | 10/26/06 | Roberts et al. | |
| A89 | 2007/0015905 | 1/18/07 | LaColla et al. | |
| A90 | 2007/0060503 | 3/15/07 | Gosselin et al. | |

LAI-2881671v1

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|--------------------|-----------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, et al. | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----|-----------------|---------------|---|---|
| | A91 | 2007/0060504 | 3/15/07 | Gosselin et al. | |
| | A92 | 10/845,976 | 5/14/04 | Storer, et al. | |
| | A93 | 11/005,443 | 12/6/04 | Gosselin et al. | |
| | A94 | 11/644,304 | 12/22/06 | Mayes, et al. | |
| | A95 | 11/516,928 | 9/06/06 | Sommadossi, et al. | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|-----|--|---------------|---|---|---|
| | B01 | CA 2252144 | 4/16/00 | Miller, et al. | | |
| | B02 | DD 140254 | 2/20/80 | Barwolff, et al. | An English language abstract is also provided. | |
| | B03 | DE 42 24 737 | 2/03/94 | Schott | An English language abstract is also provided | |
| | B04 | DE 102005012681 | 09/21/06 | Weber, Lutz | An English language abstract is also provided | |
| | B05 | EP 0 352 248 | 1/24/90 | Medivir AB | | |
| | B06 | EP 0 526 655 | 2/10/93 | Japan Tobacco Inc. | | |
| | B07 | EP 0 553 358 | 8/04/93 | Japan Tobacco Inc. | | |
| | B08 | EP 0 587 364 | 3/16/94 | Britton, et al. | | |
| | B09 | EP 0 742 287 | 11/13/96 | McGall, et al. | | |
| | B10 | FR 1 581 628 | 9/19/69 | Merck & Co. Inc. | An English language abstract is also provided | |
| | B11 | FR 2,662,165 | 11/22/91 | Univ. Pier et Curie | An English language abstract is also provided | |
| | B12 | GB 1,542,442 | 3/21/79 | Schering AG | | |
| | B13 | JP 2091022 | 3/30/90 | Univ. of Minnesota | An English language abstract is also provided | |
| | B14 | JP 61212592 | 9/20/86 | Tokyo Tanabe Co. Ltd. | An English language abstract is also provided | |
| | B15 | JP 61263995 | 11/21/86 | Takeda Chemical Ind., Ltd. | An English language abstract is also provided | |
| | B16 | JP 63215694 | 9/8/88 | Yamasa Shoyu Co. Ltd. | An English language abstract is also provided | |
| | B17 | JP 06135988 | 5/17/94 | Toagosei Chimical Ind., Ltd. | An English language abstract is also provided | |

LAI-2881671v1

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| | FILING DATE | ART UNIT |
| | June 27, 2003 | 1623 |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|---------------------------|---|----------------------|--|--|----------|
| B18 | JP 06293645 | 10/21/94 | Jpn. Kokai Tokkyo Koho | An English language abstract is also provided | |
| B19 | JP 09059292 | 3/04/97 | Yamasa Shoyu Co. Ltd. | An English language abstract is also provided | |
| B20 | WO 94/01117 | 1/20/94 | The Wellcome Foundation | | |
| B21 | WO 98/16184 | 4/23/98 | ICN Pharmaceuticals | | |
| B22 | WO 99/023104 | 5/14/99 | U.S. Dept. of Health and Human Services | | |
| B23 | WO 00/009531 | 2/24/00 | Novirio Pharmaceuticals | | |
| B24 | WO 00/025799 | 5/11/00 | Gosselin, <i>et al.</i> | | |
| B25 | WO 01/68663 | 9/20/01 | Ribapharm | | |
| B26 | WO 01/049700 | 07/12/01 | Biochem Pharma Inc. | | |
| B27 | WO 01/091737 | 12/06/01 | Sommadossi, <i>et al.</i> | | |
| B28 | WO 02/03997 | 1/17/02 | ICN Pharmaceuticals | | |
| B29 | WO 02/094289 | 5/15/02 | Hoffmann-La Roche AG | | |
| B30 | WO 02/100415 | 6/07/02 | Hoffmann-La Roche AG | | |
| B31 | WO 02/070533 | 9/12/02 | Pharmasset | | |
| B32 | WO 03/068244 | 8/21/03 | Merck & Co. Isis Pharmaceuticals | | |
| B33 | WO 03/072757 | 2/28/03 | Biota Inc. | | |
| B34 | WO 03/026589 | 4/3/03 | Idenix (Cayman) Ltd. | | |
| B35 | WO 03/026675 | 4/3/03 | Idenix (Cayman) Ltd. | | |
| B36 | WO 03/093290 | 5/06/03 | Genelabs Technologies | | |
| B37 | WO 03/039523 | 5/15/03 | Exiqon A/S | | |
| B38 | WO 03/051899 | 6/26/03 | Ribapharm Inc. | | |
| B39 | WO 03/063771 | 8/7/03 | Pharmasset | | |
| B40 | WO 03/068162 | 8/21/03 | Pharmasset | | |
| B41 | WO 03/068164 | 8/21/03 | Pharmasset | | |
| B42 | WO 03/099840 | 12/04/03 | Isis Pharmaceuticals | | |
| B43 | WO 03/100017 | 12/04/03 | Eldrup, <i>et al.</i> | | |
| B44 | WO 03/106577 | 12/24/03 | Weikard, <i>et al.</i> | | |
| B45 | WO 04/003138 | 1/08/04 | Merck & Co./Isis Pharmaceuticals | | |
| B46 | WO 04/009020 | 1/29/04 | Merck & Co./Isis Pharmaceuticals | | |

LAI-2881671vl

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT | |
| June 27, 2003 | 1623 | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|---------------------------|---|----------------------|--|--|----------|
| B47 | WO 04/028481 | 4/08/04 | Genelabs Technologies | | |
| B48 | WO 04/046159 | 6/03/04 | Hoffmann-La Roche AG | | |
| B49 | WO 04/002422 | 1/8/04 | Idenix (Cayman) Ltd. | | |
| B50 | WO 04/002999 | 1/8/04 | Idenix (Cayman) Ltd. | | |
| B51 | WO 04/003000 | 1/8/04 | Idenix (Cayman) Ltd. | | |
| B52 | WO 04/041203 | 05/21/04 | Xenopore, Inc. | | |
| B53 | WO 04/043977 | 5/27/04 | Prakash, <i>et al.</i> | | |
| B54 | WO 04/043978 | 5/27/04 | Baker, <i>et al.</i> | | |
| B55 | WO 04/044132 | 5/27/04 | Baker, <i>et al.</i> | | |
| B56 | WO 04/046331 | 06/03/04 | Idenix (Cayman) Ltd. | | |
| B57 | WO 04/052899 | 06/24/04 | Idenix (Cayman) Ltd. | | |
| B58 | WO 04/058792 | 07/15/04 | Idenix (Cayman) Ltd. | | |
| B59 | WO 04/072090 | 8/26/04 | Merck & Co., Inc. | | |
| B60 | WO 04/084796 | 10/07/04 | Pharmasset, Ltd. | | |
| B61 | WO 04/096149 | 11/11/04 | Idenix Cayman Limited | | |
| B62 | WO 04/106356 | 12/9/04 | Syddansk Universitet | | |
| B63 | WO 05/003147 | 01/13/05 | Pharmasset, Ltd. | | |
| B64 | WO 05/020884 | 03/10/05 | Idenix (Cayman) Ltd. | | |
| B65 | WO 05/020885 | 03/10/05 | Isis Pharmaceuticals, Inc. | | |
| B66 | WO 05/042556 | 05/12/05 | Genelabs Technologies, Inc. | | |
| B67 | WO 06/016930 | 02/16/06 | Intermune, Inc. | | |
| B68 | WO 06/037028 | 04/06/06 | Idenix (Cayman) Ltd | | |
| B69 | WO 06/037227 | 04/13/06 | Migenix Inc., Can. | | |
| B70 | WO 06/063717 | 6/22/06 | Universitaet Karlsruhe | | |
| B71 | WO 06/065335 | 06/22/06 | Merck & Co. Inc. | | |
| B72 | WO 06/097323 | 09/21/06 | Weber, Lutz | | |
| B73 | WO 06/100087 | 09/28/06 | Novartis AG | | |
| B74 | WO 06/121820 | 11/16/06 | Valeant Research & Development | | |
| B75 | WO 06/130532 | 12/07/06 | Novartis AG | | |
| B76 | WO 07/011777 | 01/25/07 | Novartis AG. | | |

LAI-2881671v1

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| | FILING DATE | ART UNIT |
| | June 27, 2003 | 1623 |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|--|---------------|---|---|---|
| B77 | WO 07/025304 | 01/03/07 | University of Oxford; Idenix Pharmaceuticals; <i>et al.</i> | | |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|---|---|
| C01 | ALT et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," <i>Hepatology</i> , 22 :707-717 (1995). | |
| C02 | ALT, et al., "Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation." <i>Arch. Virol.</i> 142 :589-599 (1997). | |
| C03 | ALTMANN et al., "The synthesis of l'-methyl carbocyclic thymidine and its effect on nucleic acid duplex stability," <i>Synlett</i> , Thieme Verlag, Stuttgart, DE 10 :853-855 (1994). | |
| C04 | BEIGELMAN et al., "Functionally complete analogs of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. <i>Bioorganicheskaya Khimiya</i> 12 (10):1359-1365 (1986). | |
| C05 | BEIGELMAN et al., "Epimerization during the acetolysis of 3-O-acetyl-5-O-benzoyl-1,2-O-isopropylidene-3-C-methyl-a, D-ribofuranose. Synthesis of 3'-C-methylnucleosides with the B-D-ribo-and a-D-arabino configurations," <i>Carbohydrate Research</i> , 181 :77-88 (1988). | |
| C06 | BERENGUER et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," <i>Proceedings of the Association of American Physicians</i> , 110 (2):98-112 (1998). | |
| C07 | BHOPALE et al., "Emerging drugs for chronic hepatitis C," <i>Hepatology Research</i> 32 (3):146-153 (2005). | |
| C08 | BILLICH et al., "Nucleoside phosphotransferase from malt sprouts. I. Isolation, characterization and specificity of the enzyme" <i>Biol. Chem. Hoppe-Seyler</i> , 367 :267-278 (1986). | |
| C09 | BIO et al., "Practical synthesis of a potent hepatitis C virus RNA replication inhibitor." <i>Journal of Organic Chemistry</i> 69 (19):6257-6266 (2004). | |
| C10 | BLOCH et al., "The role of the 5'-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase," <i>J. Med. Chem.</i> , 10 (5):908-12 (1967). | |
| C11 | BROWN and McFARLIN et al., "The reaction of lithium alum, um hydride with alcohols. Lithium tri-t-butoxy-aluminohydride as a new selective reducing agent", <i>J. Am. Chem. Soc.</i> 80 :5372-5376 (1958) | |
| C12 | BRYANT et al., "Antiviral L-nucleosides specific for hepatitis B virus infection," <i>Antimicrobial Agents and Chemotherapy</i> , 45 (1):229-235 (2001). | |
| C13 | CAPPELLACCI et al., "Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists." <i>Journal of Medicinal Chemistry</i> 48 (5):1550-1562 (2005). | |
| C14 | CARROLL, "Nucleoside analog inhibitors of hepatitis C virus replication," <i>Infectious Disorders: Drug Targets</i> 6 (1):17-29 (2006). | |
| C15 | CARROLL et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs." <i>J. Biol. Chem.</i> 278 (14):11979-11984 (2003). | |
| C16 | CAVELIER et al., "Studies of selective boc removal in the presence of silyl ethers," <i>Tetrahedron Letters</i> 37 : 5131-5134 (1996). | |
| C17 | CHAND et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." <i>Collection Symposium Series</i> , 7 (Chemistry of Nucleic Acid Components): 329-332 (2005). | |
| C18 | CHIARAMONTE et al., "Inhibition of CMP-sialic acid transport into Golgi vesicles by nucleoside monophates." <i>Biochemistry</i> 40 (47):14260-14267 (2001). | |

LAI-2881671v1

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11874-016-999 | 10/609,298 |
| | APPLICANT | |
| | LaColla, <i>et al.</i> | |
| | FILING DATE | ART UNIT |
| | June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|-----|--|---|
| | C19 | CLARK <i>et al.</i> , "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication." <i>Journal of Medicinal Chemistry</i> 48 (17):5504-5508 (2005). | |
| | C20 | COELMONT <i>et al.</i> , "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine," <i>Antimicrobial Agents and Chemotherapy</i> 50 (10):3444-3446 (2006). | |
| | C21 | COOK, "Improving the treatment of hepatitis C infection in the UK," <i>Expert Opinion on Pharmacotherapy</i> , (2007) Vol. 8, No. 2, pp. 183-191. | |
| | C22 | CORNBERG <i>et al.</i> , "Present and future therapy for hepatitis C virus," <i>Expert Review of Anti-Infective Therapy</i> 4 (5):781-793 (2006). | |
| | C23 | CRETTON-SCOTT <i>et al.</i> , "Pharmacokinetics of B-L-2'-deoxyctidine prodrugs in monkeys," <i>Antiviral Res.</i> , 50 :A44 (2001). | |
| | C24 | CZERNECKI <i>et al.</i> , "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," <i>J. Org. Chem.</i> , 57 :7325-7328 (1992). | |
| | C25 | DALPIAZ <i>et al.</i> , "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." <i>European Journal of Pharmacology</i> 448 (2-3):123-131 (2002). | |
| | C26 | DAVIS, "New therapies: Oral inhibitors and immune modulators," <i>Clinics in Liver Disease</i> 10 (4): 867-880 (2006). | |
| | C27 | DAVISSON <i>et al.</i> , "Synthesis of nucleotide 5'-diphosphates from 5'-O-tosyl nucleosides," <i>J. Org. Chem.</i> 52 (9):1794-1801 (1987). | |
| | C28 | DE FRANCESCO <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> 58 (1):1-16 (2003). | |
| | C29 | DING <i>et al.</i> , "Synthesis of 9-(2'-β-C-methyl-β-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." <i>Bioorganic & Medicinal Chemistry Letters</i> 15 (3):709-713 (2005) | |
| | C30 | DING <i>et al.</i> , "Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." <i>Bioorganic & Medicinal Chemistry Letters</i> 15 (3):725-727 (2005). | |
| | C31 | DUTARTRE <i>et al.</i> , "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," <i>Antimicrobial Agents and Chemotherapy</i> 50 (12):4161-4169 (2006). | |
| | C32 | ELDRUP <i>et al.</i> , "Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication," <i>Journal of Medicinal Chemistry</i> 47 (21):5284-5297 (2004). | |
| | C33 | ELDRUP <i>et al.</i> , "Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase". <i>Journal of Medicinal Chemistry</i> 47 (9): 2283-2295 (2004). | |
| | C34 | FAIVRE-BUET <i>et al.</i> , "Synthesis of 1'-deoxypsifuanosyl-dexoynucleosides as potential anti-HIV agents," <i>Nucleosides & Nucleotides</i> , 11 (7):1411-1424 (1992). | |
| | C35 | FEDOROV <i>et al.</i> , "3' -C-Branched 2' -deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties." <i>J. Med. Chem.</i> 35 (24):4567-4575 (1992). | |
| | C36 | FOX <i>et al.</i> , "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," <i>J. Am. Chem. Soc.</i> 81 : 178-187 (1959). | |
| | C37 | FRANCHETTI <i>et al.</i> , "Antitumor activity of C-methyl-β-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors." <i>Journal of Medicinal Chemistry</i> 48 (15):4983-4989 (2005). | |
| | C38 | FUJIMORI <i>et al.</i> , "A convenient and stereoselective synthesis of 2'-deoxy-β-L-nucleosides," <i>Nucleosides & Nucleotides</i> , 11 (2-4): 341-349 (1992); only CAPLUS abstract supplied. | |
| | C39 | FURUKAWA <i>et al.</i> "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," <i>Chem. Pharm. Bull.</i> , 16 (6):1076-1080 (1968). | |
| | C40 | GALDERISI <i>et al.</i> , "Antisense oligonucleoties as therapeutic agents," <i>Journal of Cellular Physiology</i> , 181 (2):251-257 (1999). | |
| | C41 | GALLO <i>et al.</i> , "2'-C-methyluridine phosphoramidite: A new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group." <i>Tetrahedron</i> 57 : 5707-5713 (2001). | |

LAI-2881671v1

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-------------------------|------------------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|---------------------------|-----|--|----------|
| | C42 | GRETCH, "Use and interpretation of HCV diagnostic tests in the clinical setting." <i>Clinics in Live Disease</i> , 1(3):547-557 (1997). | |
| | C43 | GIRARDET <i>et al.</i> , "Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides." <i>Journal of Medicinal Chemistry</i> 43(20):3704-3713 (2000). | |
| | C44 | GROUILLER <i>et al.</i> , "Novel-p-toluenesulfonylation and thionocarbonylation of unprotected thymine nucleosides," <i>Synlett</i> , 1993: 221-222 (1993). | |
| | C45 | GROUILLER <i>et al.</i> , "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." <i>J. Pharm. Belg.</i> , 47(4):381-383 (1992). | |
| | C46 | HARAGUCHI <i>et al.</i> , "Preparation and reactions of 2'-and 3'- vinyl bromides of uracil nucleosides: versatile synthons for anti-HIV agents," <i>Tetrahedron Letters</i> 32(28):3391-3394 (1991). | |
| | C47 | HARAGUCHI <i>et al.</i> , "Stereoselective synthesis of 1'-C-branched uracil nucleosides from uridine," <i>Nucleotides & Nucleosides</i> 14(3-5):417-420 (1995). | |
| | C48 | HARRY-O'KURU <i>et al.</i> , "2'-C-Alkylribonucleosides: Design, synthesis and conformation," <i>Nucleosides & Nucleotides</i> 16:1457-1460 (1997). | |
| | C49 | HATTORI <i>et al.</i> , "Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine and -uracil," <i>J. Med. Chem.</i> 41(15): 2892-2902 (1998). | |
| | C50 | HAYAKAWA <i>et al.</i> , "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: Synthesis of uracil nucleosides branched at the 2'- and 3'-positions." <i>Chemical & Pharmaceutical Bulletin</i> 35(6):2605-2608 (1987). | |
| | C51 | HOARD <i>et al.</i> , "Conversion of mono- and oligodeoxyribonucleotides to 5'-triphosphates," <i>J. Am Chem. Soc.</i> , 87(8):1785-1788 (1965). | |
| | C52 | HOLY, "Nucleic acid components and their analogs. CLIII. Preparation of 2'-deoxy-L-ribonucleosides for the pyrimidine series," <i>Collect. Czech. Chem. Commun.</i> , 37(12):4072-4087 (1972). | |
| | C53 | HREBABECKY <i>et al.</i> , "Nucleic acid components and their analogs. CXLIX: Synthesis of pyrimidine nucleosides derived from 1-deoxy-D-psicose," <i>Coll Czech Chem Com.</i> 37: 2059-2064 (1974). | |
| | C54 | HREBABECKY <i>et al.</i> , "Synthesis of 7- and 9b-D-psicofuranosylguanine and their 1'-deoxy derivatives." <i>Collection Czechoslov. Chem. Commun.</i> , 39: 2115-2123 (1974). | |
| | C55 | IGLESIAS <i>et al.</i> , "Complete and regioselective deacetylation of peracetylated uridines using a lipase." <i>Biotechnology Letters</i> 22: 361-365 (2000). | |
| | C56 | IIMORI <i>et al.</i> , "2'-C-, 3'-C-, and 5'-C-methylsangivamycins: Conformational lock with the methyl group." <i>Tetrahedron Letters</i> 32(49):7273-7276 (1991). | |
| | C57 | IIMORI <i>et al.</i> , "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." <i>Nucleic Acids Symposium Series , Nineteenth Symposium on Nucleic Acids Chemistry</i> , 27:169-170 (1992). | |
| | C58 | IINO T. <i>et al.</i> , "Nucleosides and nucleotides 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines." <i>Nucleosides & Nucleotides</i> , 15(1-3): 169-181 (1996). | |
| | C59 | IKEGASHIRA <i>et al.</i> , "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors." <i>Journal of Medicinal Chemistry</i> 49(24):6950-6953 (2006). | |
| | C60 | IMAI <i>et al.</i> , "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides." <i>J. Org. Chem.</i> 34(6):1547-1550 (1969). | |
| | C61 | ITOH <i>et al.</i> , "Divergent and sterocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position," <i>J. Org. Chem.</i> 60(3): 656-662 (1995). | |
| | C62 | KAKEFUDA <i>et al.</i> , "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: Synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." <i>Tetrahedron</i> 49(38): 8513-8528 (1993) | |

LAI-2881671v1

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-------------------------|------------------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|---------------------------|-----|---|----------|
| | C63 | KAMAIKE et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, J6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nucleosides and Nucleotides, 15(1-3):749-769 (1996). | |
| | C64 | KANEKO et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972). | |
| | C65 | KAWANA et al., "The deoxygenation of tosylated adenosine derivatives with Grignard reagents," Nucleic Acids Symp. Ser. 17:37-40 (1986). | |
| | C66 | KEMPE et al., "Selective 2'-benzoylation at the cis 2', 3'-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures," Nucleic Acids Res. 10(21):6695-6714 (1982). | |
| | C67 | KERR et al., "N-4-(Dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications," J. Pharm. Sci. 83(4): 582-586 (1994). | |
| | C68 | KLUMPP et al., "The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture," Journal of Biological Chemistry 281(7):3793-3799 (2006). | |
| | C69 | KIM et al., "A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein," Molecular Pharmaceutics 1(2):117-127 (2004). | |
| | C70 | LAI et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependent RNA polymerase," J. Virol. 73(12):10129-10136 (1999). | |
| | C71 | LANDOWSKI, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics 316(2): 572-580 (2006). | |
| | C72 | LAVAIRE et al., "3'-deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," Nucleosides & Nucleotides 17(12): 2267-2280 (1998). | |
| | C73 | LE POGAM et al., "In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance," Virology 351: 349-359 (2006). | |
| | C74 | LE POGAM et al., "Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerases inhibitors of the hepatitis C virus," Journal of Virology 80(12): 6146-6154 (2006). | |
| | C75 | LEYSSEN et al., "Perspectives for the treatment of infections with Flaviviridae," Clinical Microbiology Reviews (Washington D.C.) 13(1): 67-82 (2000). | |
| | C76 | LIN et al., "Synthesis of several pyrimidine L-nucleoside analogues as potential antiviral agents," Tetrahedron Letters 51(4): 1055-1068 (1995). | |
| | C77 | LOPEZ-HERRERA et al., "A new synthesis of 2-C methyl-D-ribono-1, 4-lactone and the C-/(C-13 fragment of methynolide," J. Carbohydrate Chemistry 13(5): 767-775 (1994). | |
| | C78 | LOPEZ APARICIO et al., "Synthesis of saccaric acid derivatives," Carbohydrate Res. 129:99 (1984). | |
| | C79 | MAGA et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J. 294(Part2): 381-385 (1993). | |
| | C80 | MANSOUR et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1. | |
| | C81 | MARKLAND et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy 44 (4): 859-866 (2000). | |
| | C82 | MARTIN et al., "Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)," J. Med. Chem. 33(8): 2137-2145 (1990). | |
| | C83 | MARTIN et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy- β -D-pisofuranosyl)nucleoside," Tetrahedron 50(22): 6689-6694 (1994). | |
| | C84 | MATSUDA et al., "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: Synthesis of 2'-branched-chain sugar pyrimidine nucleosides (Nucleosides and Nucleotides. LXXXI)," Chem. Pharm. Bull. 36(3):945-953 (1988). | |

LAI-2881671v1

| EXAMINER | DATE CONSIDERED |
|---|------------------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

| | |
|------------------------|-----------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|------|--|---|
| | C85 | MATSUDA et al., "Nucleosides and nucleotides. 104. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides." <i>Nucleosides & Nucleotides</i> 11 (2/4): 197-226 (1992). | |
| | C86 | The Merck Index, 12th edition, 1996, Page 275 | |
| | C87 | MIKHAILOV et al., "Hydrolysis of 2'- and 3'-C-methyluridine 2'-, 3'-monophosphates and interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of uridine monophosphates," <i>J. Org. Chem.</i> 57 : 4122-4126 (1992). | |
| | C88 | MIKHAILOV et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," <i>Nucleosides & Nucleotides</i> 10 (1-3): 339-343 (1991). | |
| | C89 | MILES et al., "Circular dichroism of nucleoside derivatives. IX. Vicinal effects on the circular dichroism of pyrimidine nucleosides." <i>Journal of the American Chemical Society</i> 92 (13):3872-3881 (1970). | |
| | C90 | MOORE et al., "Synthesis of nucleotide analogues that potently and selectively inhibit human DNA primase." <i>Biochemistry</i> 41 (47): 14066-14075 (2002). | |
| | C91 | MOISEYEV et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." <i>FEBS Letters</i> 404 (2,3): 169-172 (1997) | |
| | C92 | NISHIGUCHI et al., "Methods to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy," <i>Hepatology</i> 33 (1): 241-247 (2001). | |
| | C93 | NISHIMURA et al., "Studies on synthetic nucleosides. Trimethylsilyl derivatives of pyrimidine and purines," <i>Chemical & Pharmaceutical Bulletin</i> 12 : 352-356 (1964). | |
| | C94 | NOVAK & SORM, "Nucleic acid components and their analogues. CXX. 2-C-methyl-D-ribose and its derivatives," <i>Collection Czechoslov. Chem. Commun.</i> 34 :857-866 (1969). | |
| | C95 | NOVAK, "Chiroptical properties of 2-methyl-1,4-lactones; Revised absolute configuration of 2-deoxy-2-C-methyl-erythro-D-pentono-1, 4-lactones," <i>Collection Czechoslov. Chem. Commun.</i> 39 :869-882 (1974). | |
| | C96 | OIVANEN et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3', 5'-cyclic monophosphates," <i>J. Chem. Soc. Perkin Trans. 2</i> : 309-314 (1994). | |
| | C97 | PAGLIARO et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," <i>Recenti Progressi in Medicina</i> , 97 (12): 741-750 (2006). | |
| | C98 | PIERRA et al., "Comparative studies of selected potential prodrugs of B-L-dC, a potent and selective anti-HBV agent." <i>Antiviral Res.</i> , 50 :A79 (2001), Abstract no. 138. | |
| | C99 | PIERRA et al., "NM 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Nucleosides, Nucleotides and Nucleic Acids</i> 24 (5-7): 767-770 (2005). | |
| | C100 | PIERRA et al., "Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Journal of Medicinal Chemistry</i> 49 (22): 6614-6620 (2006). | |
| | C101 | REIST et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." <i>Journal of Organic Chemistry</i> 27 :3279-3283 (1962). | |
| | C102 | ROBINS et al., "Purine Nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their [alpha] anomers." <i>Journal of Organic Chemistry</i> 35 (3): 636-639 (1970). | |
| | C103 | ROQUE-AFONSO et al., "Performance of TRUGENE hepatitis C virus 5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination." <i>Journal of Viral Hepatitis</i> 9 (5): 385-389 (2002). | |
| | C104 | RONG et al., "The Synthesis and conformation of 2'- and 3'-hypermodified tricyclic nucleosides and their use in the synthesis of novel 2'- or 3'-isomeric 4(7)-substituted isoxazolidine-nucleosides." <i>Tetrahedron</i> 50 (16): 4921-4936 (1994). | |

LAI-2881671v1

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-------------------------|------------------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|---------------------------|--|----------|
| C105 | SAMANO et al., "Synthesis and radical-induced ring-opening reactions of 2'-deoxyadenosine-2'-spirocyclopropane and its uridine analogue. Mechanistic probe for ribonucleotide reductases," <i>J Am Chem Soc</i> , 114 : 4007-08 (1992) | |
| C106 | SAMANO et al., "Nucleic acid related compounds. 77. 2',3'-didehydro-2', 3'-dideoxy-2' (and 3')-methylnucleosides via [3,3]-sigmatropic rearrangements of 2'(and 3')-methylene-3'(and 2')-O-thiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analogue," <i>Can. J. Chem.</i> 71 : 186-191 (1993) | |
| C107 | SANDHU et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." <i>Drug Metabolism and Disposition</i> 32(11) : 1254-1259 (2004) | |
| C108 | SAKTHIVEL et al., "Direct SNAr amination of fluorinated imidazo[4,5-c]pyridine nucleosides: efficient syntheses of 3-fluoro-3-deazaadenosine analogs." <i>Tetrahedron Letters</i> 46(22) : 3883-3887 (2005). | |
| C109 | SAKTHIVEL et al. "Electrophilic fluorination of 5-(cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." <i>Synlett</i> 2005 , 10 : 1586-1590 (2005). | |
| C110 | SALADINO et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," <i>J. Chem. Soc., Perkin Trans. I</i> , 21 : 3053-3054 (1994). | |
| C111 | SATO, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." <i>Tetrahedron Letters</i> (1980), 21(20) , 1971-4. | |
| C112 | SATO et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." <i>Bulletin of the Chemical Society of Japan</i> , 56(9) : 2680-2699 (1983). | |
| C113 | SCHEIBLER, "Ueber das Saccharin und die Saccharinsaure," <i>Chemische Berichte</i> 13 :2212-2217 (1880). In German. | |
| C114 | SCHIFF, "Emerging strategies for pegylated interferon combination therapy," <i>Nature Clinical Practice Gastroenterology and Hepatology</i> 4(SUPPL. 1) : S17-S21 (2007). | |
| C115 | SCHMIT et al., "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," <i>Bioorg. & Med. Chem. Lett.</i> 4(16) : 1969-1974 (1994). | |
| C116 | SERAFINOWSKI et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," <i>Tetrahedron</i> , 56(2) :333-339 (1999). | |
| C117 | SHIM, "Recent patents on nucleoside and nucleotide inhibitors for HCV," <i>Recent Patents on Anti-Infective Drug Discovery</i> 1(3) : 323-331 (2006). | |
| C118 | SMITH et al., "Synthesis of new 2'- β -C-methyl related triciribine analogues as anti-HCV agents." <i>Bioorganic & Medicinal Chemistry Letters</i> 14(13) : 3517-3520 (2004). | |
| C119 | SONG et al., "Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport." <i>Molecular Pharmaceutics</i> 2(2) : 157-167 (2005). | |
| C120 | SORBERA et al., "Valopicitabine: anti-hepatitis C virus drug RNA-directed RNA polymerase (NS5B) inhibitor," <i>Drugs of the Future</i> 31(4) : 320-324 (2006). | |
| C121 | SOWDEN, "The Saccharinic Acids," <i>Adv. Carbohydrate Chem.</i> 12 :43-46 (1957). | |
| C122 | SPARDARI et al., "L-Thmidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth." <i>Journal of Medicinal Chemistry</i> 35(22) : 4214-4220 (1992). | |
| C123 | STANDRING et al., "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," <i>Antiviral Chem. & Chemother.</i> 12 (Suppl. 1) : 119-129 (2001). | |
| C124 | STUYVER et al., "Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture." <i>Antimicrobial Agents and Chemotherapy</i> 47(1) : 244-254 (2003). | |
| C125 | SUNDBERG et al., Advanced Organic Chemistry, Part b, pages 232 and 236 (1990). | |
| C126 | TAKENUKI et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." <i>Chemical & Pharmaceutical Bulletin</i> 38(11) : 2947-2952 (1990). | |

LAI-2881671v1

| EXAMINER | DATE CONSIDERED |
|---|------------------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|------------------------|-----------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 11874-016-999 | 10/609,298 |
| APPLICANT | |
| LaColla, <i>et al.</i> | |
| FILING DATE | ART UNIT |
| June 27, 2003 | 1623 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|------|--|---|
| | C127 | TANG et al., "2'-C-branched ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C- β -methylcytidine and their incorporation into oligonucleotides." <i>J. Org. Chem.</i> 64 (3): 747-754 (1999). | |
| | C128 | TRITSCH et al., "3'- β -ethynyl and 2'-deoxy-3'- β -ethynyl adenosines: First 3'- β -branched adenosine substrates of adenosine deaminase," <i>Bioorg. & Med. Chem. Lett.</i> 10 (2): 139-141 (2000). | |
| | C129 | TUNITSKAYA et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," <i>FEBS Letters</i> , 400 (3): 263-266 (1997). | |
| | C130 | TYRSTED et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," <i>Biochem. Biophys. Acta.</i> 155 (2): 619-622 (1968). | |
| | C131 | USUI et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," <i>Chem. Pharm. Bull.</i> , 34 (1):15-23 (1986). | |
| | C132 | VASSILEV et al., "Bovine viral diarrhea virus induced apoptosis correlates with increased intracellular viral RNA accumulation." <i>Virus Research</i> , 69 : 95-107 (2000). | |
| | C133 | VERRI et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents," <i>Molecular Pharmacology</i> , 51 (1): 132-138 (1997). | |
| | C134 | VERRI et al., "Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues," <i>Biochem. J.</i> 328 (1): 317-320 (1997). | |
| | C135 | VON BUREN et al., "Branched oligodeoxynucleotides: Automated synthesis and triple helical hybridization studies." <i>Tetrahedron</i> 51 (31): 8491-8506 (1995). | |
| | C136 | VON JANTA-LIPINISKI et al., "Newly synthesized L-enantiomers of 3'-fluoro-modified β -2'-deoxyribonucleoside 5'-triphosphates inhibit hepatitis B DNA polymerase but not the five cellular SNA Polymerases α , β , γ , δ and ϵ nor HIV-1 reverse transcriptase," <i>J. Medicinal Chemistry</i> 41 (12): 2040-2046 (1998). | |
| | C137 | WAGNER et al., "Preparation and synthetic utility of some organotin derivatives of nucleosides," <i>J. Org. Chem.</i> , 39 (1):24-30 (1974). | |
| | C138 | WALCZAK et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," <i>Acta Chemica Scand.</i> 45 : 930-934 (1991). | |
| | C139 | WALTON et al., "Branched-chain sugar nucleosides: V. Synthesis and antiviral properties of several branched-chain sugar nucleosides," <i>Antiviral Nucleosides</i> 12 : 306-309 (1969). | |
| | C140 | WHISTLER AND BEMILLER, "[118] 'a'-D-glucosaccharino-1,4-lactone," <i>Methods in Carbohydrate Chemistry</i> , 2 :484-485 (1963). | |
| | C141 | WOHNSLAND et al., "Viral determinants of resistance to treatment in patients with hepatitis C," <i>Clinical Microbiology Reviews</i> 20 (1): 23-38 (2007). | |
| | C142 | WOLFE et al., "A concise synthesis of 2'-C-Methylribonucleosides." "Tetrahedron Letters" 36 (42): 7611-14 (1995). | |
| | C143 | WU et al., "A new stereospecific synthesis of [3.1.0] bicyclic cyclopropano analog of 2',3'-dideoxyuridine." <i>Tetrahedron</i> 46 : 2587-2592 (1990). | |
| | C144 | ZEMLICKA et al. "Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. VIII. The preparation of 2'(3')-O-L-phenylalanyluridine, -cytidine, -adenosine, -inosine, -guanosine and 2'-deoxy-3' O-L-phenylalanyladenosine," <i>Collection Czecoslov. Chem. Commun.</i> 43 (13): 3755-3768 (1969). | |
| | C145 | ZEMLICKA et al., "Substrate specificity of ribosomal peptidyltransferase. Peditidyltransferase. Effect of modifications in the heterocyclic, carbohydrate and amino acid moiety of 2'(3)-O-L-phenyladenosine." <i>Biochemistry</i> 14 (24): 5239-5249 (1975) | |
| | C146 | ZINICHENKO et al., "Substrate specificity of uridine and purine nucleoside phosphorylases of the whole cells of <i>Escherichia coli</i> ." <i>Nucleic Acids Research, Symposium Series No. 18.</i> , pp. 137-140 (1987). | |

LAI-2881671v1

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |